The $2 Trillion Valuation Debate Skips What Anthropic Knows 
Pharmacore secures funding to improve medication regimen reviews in long-term care Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
Synfini, Inc. Spins Out of SRI International to Bring Novel Molecular Discovery Platform to Market
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Synfini, Inc. Spins Out of SRI International to Bring Novel Molecular Discovery Platform to Market
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ:…
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ:…
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
–Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population…
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
–Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population…
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE…
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE…
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of…
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of…